June 19th 2024
A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.
October 4th 2023
Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.
December 12th 2022
Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.
August 16th 2022
Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.
Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.
August 9th 2022
Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.
Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.
August 8th 2022
Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.
Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.
August 3rd 2022
Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.
August 2nd 2022
A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.
Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.
A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.
July 26th 2022
Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.
Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.
July 21st 2022
Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.
July 19th 2022
Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.
Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice
July 13th 2022
Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.
July 12th 2022
Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.